Healthcare
Genelux Corporation(GNLX)
Live Price
Offline$2.97
+4.04% today
1Y Change
-2.79%
Window
Jun 26, 2025 โ Jun 18, 2026
- Market Cap
- $100.00M
- Revenue Growth
- 0.0%
- EPS Growth
- +9.5%
- Dividend Yield
- 0.0%
Coverage: 246 bars ยท Jun 26, 2025 โ Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Genelux Corporation (GNLX) is a Healthcare stock with a market cap of $100.00M and listed on NASDAQ. The stock last traded around $2.96 and down 2.8% across the available one-year price window (Jun 26, 2025 โ Jun 18, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +9.5%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +9.5%, free cash flow -22.0% with operating margin -415175.0% and ROIC -251.1%. Valuation already assumes a fairly strong business story at price/sales 12413.6. Stock Foundry combines GNLX price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
0.0% vs +7.6% peer median
Operating Margin
Below sector median
-415175.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 5, 2026, but the surprise data is still limited.
The setup is mixed rather than one-directional
Revenue is 0.0% and EPS is +9.5%, while operating margin sits near -415175.0%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -4.5% over the next 5 trading days and finished higher after 2 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 5, 2026 | โ | +3.6% | +7.2% | +8.3% |
2026 Mar 19, 2026 | -9.1% | -5.5% | +3.5% | +9.8% |
2025 Nov 5, 2025 | +8.7% | -32.4% | -24.4% | -40.7% |
Benchmark Edge
GNLX vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
GNLX
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
GNLX Max Drawdown
-72.09%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for GNLX and SPY.
Company Overview
Genelux Corporation
NASDAQ Global Market
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary, modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small-cell lung cancer. The company is also developing V2ACT Immunotherapy for the treatment of pancreatic cancer; and V-VET1 to treat hematologic and solid cancer. The company was incorporated in 2001 and is headquartered in Westlake Village, California.
- Leadership
- Thomas D. Zindrick
- IPO Date
- Jan 26, 2023
- Employees
- 24
- Street Address
- 2625 Townsgate Road
- Mailing
- Westlake Village, CA, 91361
- Region
- Westlake Village, CA, US
- Reporting Currency
- USD
- Investor Line
- 858 483 0024
- Last Updated
- Apr 29, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 12413.6
- Price/Book
- 8.5
Growth
- Revenue
- 0.0%
- EPS
- +9.5%
- Free Cash Flow
- -22.0%
Profitability
- Gross Margin
- -3537.5%
- Operating Margin
- -415175.0%
- Net Margin
- -401812.5%
- ROE
- -153.3%
- ROIC
- -251.1%
Balance Sheet
- Debt/Equity
- 0.15
- Current Ratio
- 2.43
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.